ArticleJournal of clinical microbiology2006
Pyrosequencing as a rapid tool for identification of GES-type extended-spectrum beta-lactamases.
Article in Journal of clinical microbiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Genomic Characterization of 16S rRNA Methyltransferase-ProducingAntibiotics (Basel, Switzerland) · 2024Article
- Genomic Characterization of Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2024Article
- Genomic Characterization of IMP-ProducingMicroorganisms · 2023Article
- Structural and Functional Aspects of Class A Carbapenemases.Current drug targets · 2016Review
- Non-phenotypic tests to detect and characterize antibiotic resistance mechanisms in Enterobacteriaceae.Diagnostic microbiology and infectious disease · 2013Review
- Rapid detection of aac(6')-Ib-cr quinolone resistance gene by pyrosequencing.Journal of clinical microbiology · 2010Article
- Typing of SHV extended-spectrum beta-lactamases by pyrosequencing in Klebsiella pneumoniae strains with chromosomal SHV beta-lactamase.Antimicrobial agents and chemotherapy · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A pyrosequencing technique was used for identification of extended-spectrum beta-lactamases (ESBLs) of GES type. These beta-lactamases are isolated increasingly emerging in gram-negative bacteria worldwide. This rapid and reliable identification method is interesting, since GES variants, including not only expanded-spectrum cephalosporins but also carbapenems, cephamycins, and monobactams, are the only ESBLs that possess different hydrolysis profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.